Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a key senator charged Wednesday, in the latest effort by Democrats to pressure drug companies on the ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Arizona sued drug manufacturer GlaxoSmithKline over what it calls deceptive practices involving the inhaled corticosteroid Flovent that endangered asthma patients. The lawsuit filed Thursday in ...

India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...

Rather than solely betting on a bounce or trend reversal in the broader index, look to stocks like Castrol India, ...

Net Sales at Rs 949.42 crore in December 2024 up 17.9% from Rs. 805.26 crore in December 2023. Quarterly Net Profit at Rs.

Feb 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the BSE.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...